For years, the advice was simple. Eat more pomegranates. Add walnuts. Throw berries on everything. The polyphenols would do something good for you, even if nobody could say exactly what.

The results, though, were always oddly inconsistent. One study found a benefit. The next found nothing. A third found an effect that vanished on closer inspection.

It looked like the usual noise of nutrition research. Small samples, short durations, the general messiness of studying real diets in real people.

But there was another explanation hiding underneath all of it. Whether any of those studies worked for you may have depended on something no one was measuring. Which bacteria happen to live in your gut.

That variable has a name now.

Urolithin A.

And the story of how it went from an overlooked gut metabolite to a $50-a-month longevity supplement says as much about how supplement science gets marketed as it does about mitochondria.

What Urolithin A Actually Is

Urolithin A is not something you eat. It’s something your gut makes — sometimes.

The raw materials come from ellagitannins, polyphenols found in pomegranates, walnuts, and berries. On their own, ellagitannins do very little; they’re poorly absorbed. Your gut bacteria break them down first into ellagic acid, and then — in some people — a further conversion turns ellagic acid into urolithin A.

That last step is the catch. It depends on specific microbes, primarily species of Gordonibacter and related bacteria. If your microbiome contains them, you produce urolithin A after eating a pomegranate. If it doesn’t, you don’t — no matter how many pomegranates you eat.

This is why urolithin A matters mechanistically.

In laboratory and animal studies, it appears to stimulate mitophagy — the cellular housekeeping process that identifies worn-out mitochondria and recycles them. As we age, mitophagy slows down. Damaged mitochondria accumulate, cells produce less energy, and oxidative stress rises. Urolithin A, in preclinical models, seems to help clear the backlog.

That’s a genuinely interesting mechanism. But the mechanism is where most articles start and stop.

The more revealing question is what happens next.

What happens when you take a compound that only some people can make, and study it in populations that are silently a mix of both?

The Hidden Variable in Decades of Diet Research

Here’s the detail that reframes the whole field. When researchers investigated ellagitannin-rich foods over the years, they were unknowingly studying two different populations at once.

Estimates vary by region and method, but a large share of people — often cited around 40 to 60 percent in Western cohorts — are natural non-producers or weak producers of urolithin A. In one controlled study, only about 12 percent of participants had detectable urolithin A at baseline, and even after a dose of pomegranate juice, only around 40 percent converted the precursors meaningfully.

Sit with what that means for the older research. Suppose you run a pomegranate trial on a hundred people. If half of them physically cannot produce the metabolite thought to be responsible for the benefit, your results get diluted toward nothing. The responders’ gains get averaged against the non-responders’ flat lines. The signal blurs.

What looked for years like weak or contradictory evidence for “polyphenol health benefits” may partly have been a measurement problem. A real effect in some people, hidden inside a population average that lumped them together with people for whom the intervention was biologically inert.

The food wasn’t necessarily failing. It was working for a subset, and the study design couldn’t see it. This is the part the supplement marketing gets right, and then quietly weaponizes.

Why Some Guts Make Urolithin A and Others Don’t

If producer status matters this much, the obvious question is what determines it — and whether you can change yours.

The short answer is that it comes down to which bacteria colonize your gut, and that’s shaped by a tangle of factors.

Diet plays a role, since the bacteria that perform the conversion tend to thrive in more diverse, fibre-rich microbiomes. Producers, on average, show higher overall gut-bacterial diversity than non-producers. But diversity isn’t the whole story. Some people simply lack the specific converting species almost entirely, and no amount of pomegranate juice conjures bacteria that aren’t there.

Researchers have started sorting people into rough categories based on what their gut produces.

Some convert ellagic acid efficiently into urolithin A. Others produce a mix of related metabolites. A third group produces essentially none. These patterns appear across very different populations worldwide, which suggests they’re a stable feature of human gut ecology rather than a quirk of one region’s diet.

The practical implication is uncomfortable for anyone hoping for a simple fix. You can feed the bacteria you have, but you can’t easily install the ones you’re missing. Producer status can shift somewhat with sustained dietary change, but for a true non-producer, “just eat more berries” is not reliable advice.

That, more than anything, is what makes urolithin A different from most nutrition stories — the input and the outcome are separated by an ecosystem you didn’t choose.

From Biological Insight to Sales Pitch

The producer/non-producer finding is real science. It’s also the single most effective marketing argument the urolithin A industry has.

The pitch writes itself: your gut might not make this longevity molecule, so you can’t rely on food — you need to take it directly, as a standardized dose, from us.

And there’s a defensible logic to it.

Direct supplementation does bypass the microbiome lottery. In the same study, taking urolithin A directly produced more than six times the blood levels that pomegranate juice did, and it did so regardless of producer status.

But notice how neatly a genuine biological insight has been converted into a reason to buy a product. “Some people don’t produce much urolithin A from food” is true. “Therefore everyone should supplement it” does not follow.

A natural producer eating a Mediterranean-style diet is already generating urolithin A. They’re also getting the hundreds of other compounds in whole pomegranates, walnuts, and berries that a purified supplement doesn’t contain. For them, the marginal value of a standalone dose is far less obvious than the advertising implies.

There’s a subtler sleight of hand, too.

The marketing presents direct supplementation as the solution to a problem — your unreliable microbiome — while rarely mentioning that a producer’s microbiome isn’t a problem at all.

It skips the question worth asking most.

If you don’t know your producer status, you don’t actually know whether you’re the person the supplement is for.

What the Human Evidence on Urolithin A Shows

Strip away the mechanism and the marketing, and the direct human evidence is best described as promising but modest — and narrower than it sounds.

The most-cited trial gave middle-aged adults urolithin A for four months. It reported improvements in muscle strength of roughly 12 percent, plus meaningful gains in aerobic endurance and walking performance.

Those are real, encouraging numbers.

But the same trial did not hit its primary endpoint. Peak power output showed no significant improvement. A result that misses its main pre-specified target while succeeding on secondary measures is worth taking seriously, not dismissing. It’s still a long way from the “clinically proven” tone of the supplement copy.

The trial also found reduced markers of inflammation and improved mitochondrial gene expression in muscle biopsies. That strengthens the biological plausibility.

Broader claims — for brain aging, cardiovascular disease, immune function — mostly rest on animal models or early exploratory endpoints, not settled human outcomes.

And there’s a structural issue your skepticism should flag.

A large fraction of the human urolithin A trials involve the same company that sells the branded ingredient. That involvement runs through funding, authorship, or supply of the compound itself.

It doesn’t make the findings wrong.

It does mean the evidence base is unusually concentrated in the hands of the parties with the most to gain, and independent replication matters more than usual.

So Should You Consider It?

The honest answer runs through your gut, not the supplement label.

If you eat a varied diet with regular pomegranate, berries, and nuts, and you’re a natural producer, you’re already making urolithin A. You’re also getting everything else those foods provide.

A supplement adds a purified version of one compound you’re generating anyway.

If you’re a non-producer — and a meaningful share of people are — then direct supplementation is the one scenario where the marketing logic actually holds.

It’s the only reliable way to get the molecule your microbiome won’t make.

The catch is that most people have no idea which group they’re in. Producer status can be estimated through specialized microbiome or metabolite testing. But it’s not something a standard checkup reveals.

That uncertainty is the real takeaway.

Urolithin A is a rare case where the same intervention is plausibly worthwhile for some people and close to redundant for others. And the deciding factor is invisible without testing.

Bottom Line

Urolithin A is a legitimately interesting molecule attached to a legitimately interesting mechanism.

But it’s also a case study in how individual variability gets flattened.

First by decades of diet research that averaged producers and non-producers into an inconclusive blur. Then by marketing that took that same variability and sold it back to everyone as a reason to buy.

The human evidence is real but early, modest, and heavily tied to a single commercial source.

And the most important number in the entire story isn’t the 12 percent strength gain in the headline trial. It’s the roughly half of people whose own gut quietly determines whether any of this applies to them at all.

---

References

1. Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016;22(8):879–888. https://www.nature.com/articles/nm.4132
2. Singh A, D’Amico D, Andreux PA, et al. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. European Journal of Clinical Nutrition. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821002/
3. Singh A, D’Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633. https://pubmed.ncbi.nlm.nih.gov/35584623/
4. García-Villalba R, Tomás-Barberán FA, et al. Urolithins: a comprehensive update on their metabolism, bioactivity, and associated gut microbiota. Molecular Nutrition & Food Research. 2022. (UM-0 prevalence ~10% across ages 5–90 in a cohort of 839.) https://onlinelibrary.wiley.com/doi/full/10.1002/mnfr.202101019
5. Urolithin A: a multi-target therapeutic candidate derived from the gut microbiota for obesity and metabolic dysfunction. Frontiers in Endocrinology. 2026. (Approximately one-third of individuals — UM-0 — cannot produce urolithin A; age-dependent metabotype shifts.) https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1786776/full
6. González-Sarrías A, García-Villalba R, Tomás-Barberán FA, et al. Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in individuals consuming pomegranate: a randomized clinical trial. 2017. (Metabotype clustering may explain controversial pomegranate benefits.) https://pubmed.ncbi.nlm.nih.gov/27879044/